Ligand Pharmaceuticals | LGND - Ebitda

Aktienkurs
204.92
Täglich Wechseln
-0.72 -0.35%
Monatlich
-7.38%
Jährlich
96.53%
Q2 Prognose
199.33




Ebitda Veränderung Datum
Agenus USD -10.11M 19.02M 2025-03
Amgen USD 5.14B 775M 2025-12
Anika Therapeutics USD 4.54M 3.67M 2025-12
Arrowhead Research USD 64.2M 223.53M 2025-09
Baxter International USD 426M 36M 2025-09
Bristol-Myers Squibb USD 4.24B 967M 2025-09
Eli Lilly USD 7.88B 378.1M 2025-09
Enviri Corporation USD 70.13M 4.29M 2025-12
Gilead Sciences USD 4.03B 628M 2025-09
GlaxoSmithKline GBP 3.36B 179M 2025-09
Glaxosmithkline GBP 4.75B 1.52B 2025-09
Heron Therapeutics USD -3.88M 5.63M 2024-09
Insmed USD -314.19M 31.48M 2025-12
Intrexon USD -24.7M 2.92M 2024-06
Ionis Pharmaceuticals USD -157.12M 307.36M 2025-09
Karyopharm Therapeutics USD -26.2M 1.83M 2024-09
Ligand Pharmaceuticals USD 150.32M 129.42M 2025-09
MacroGenics USD 21.95M 55.39M 2025-09
Merck USD 8.39B 1.97B 2025-09
Pacira USD 38.71M 10.65M 2025-12
Pfizer USD 6.08B 351M 2025-09
Rigel Pharmaceuticals USD -4.17M 798K 2023-09
Veracyte USD 42.31M 2.58M 2025-12